Last reviewed 2026-04-20 · How we verify

MVA-BN-HIV

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Upper Respiratory Tract Infection
• Malaria
• Headache
• Neutropenia
• Blood Sodium Decreased
• Nasopharyngitis
• Rhinitis
• Myalgia
• Diarrhoea
• Bronchitis
• Tonsillitis
• Blood Urea Decreased

Key clinical trials

• Safety, Immunogenicity, Efficacy of Ad26.Mos4.HIV, MVA-BN-HIV and PGT121, PGDM1400, and VRC07-523LS in HIV-1-Infected Adults (PHASE1, PHASE2)
• An Immunogenicity and Safety Trial of MVA-BN in Adults Living With HIV for the Prevention of Mpox Infection, in Kinshasa, DRC (PHASE2)
• Evaluation of Long-term Immunogenicity of a Boost Dose of MVA-BN Vaccine
• Safety and Efficacy of Neutralizing Antibodies and Vaccination for Induction of HIV Remission (PHASE1)
• Ad26.ZEBOV Booster in HIV+ Adults Previously Vaccinated With Ad26.ZEBOV/MVA-BN-Filo (EBOVAC HIV+ Booster Study) (PHASE2)
• Safety, Tolerability and Immunogenicity Study of 3 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo in Healthy Adults, Children and Human Immunodeficiency Virus Positive (HIV+) Adults (PHASE2)
• Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection (PHASE2)
• Safety and Immunogenicity of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in HIV Infected Patients (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• MVA-BN-HIV CI brief — competitive landscape report
• MVA-BN-HIV updates RSS · CI watch RSS
• Henry M. Jackson Foundation for the Advancement of Military Medicine portfolio CI